DHR vs MS: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
Morgan Stanley · Financial Services
$223.17
-1802.9% upside to fair value
Grade D
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
MS trades at a lower forward P/E
(20.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MS |
| Current Price |
$177.17 |
$223.17 |
| Fair Value Estimate |
$192.90 |
$-3,800.42 |
| Upside to Fair Value |
+8.9%
|
-1802.9%
|
| Market Cap |
$125.4B |
$352.0B |
| Forward P/E |
34.1x
|
20.1x
|
| EV / EBITDA |
20.8x
|
21.9x
|
| Price / Sales |
5.1x
|
2.9x
|
| Price / FCF |
23.7x
|
-334.6x
|
| Revenue Growth YoY |
+3.7%
|
+18.8%
|
| Gross Margin |
60.7%
|
58.0%
|
| Operating Margin |
21.0%
|
19.5%
|
| Return on Equity |
7.1%
|
16.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Morgan Stanley is a leading global financial services firm with a strong focus on wealth management and institutional securities, generating $70.6 billion in net revenues in 2025. The company benefits from a durable competitive moat driven by its fee-based wealth franchise, strong profitability with a 15.1% net margin, and steady capital returns. However, the stock is significantly overvalued, tr…
Accumulation Zones
| Metric |
DHR |
MS |
| Zone Low |
$144.68 |
$-2,850.32 |
| Zone High |
$163.97 |
$-3,230.36 |
| In Buy Zone? |
No
|
No
|